Summit Therapeutics (SMMT) Notes Payables (2021 - 2024)

Summit Therapeutics (SMMT) has 4 years of Notes Payables data on file, last reported at $24.5 million in Q3 2024.

• Quarterly Notes Payables fell 75.5% year-over-year to $24.5 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $24.5 million (down 75.5% YoY) and the FY2022 annual result came in at $19.8 million, changed N/A from the prior year.
• Notes Payables fell to $24.5 million in Q3 2024, from $100.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $100.0 million in Q3 2023 to a low of $19.8 million in Q4 2022.
• A 4-year average of $59.8 million and a median of $55.0 million in 2021 frame the typical range for Notes Payables.
• The widest YoY moves for Notes Payables: up 75.5% in 2024, down 75.5% in 2024.
• Tracing SMMT's Notes Payables over 4 years: stood at $55.0 million in 2021, then slumped by 64.03% to $19.8 million in 2022, then soared by 405.82% to $100.0 million in 2023, then plunged by 75.5% to $24.5 million in 2024.
• The last three Notes Payables figures came in at $24.5 million (Q3 2024), $100.0 million (Q2 2024), and $100.0 million (Q3 2023), per Business Quant data.